Dasatinib and Chronic Myeloid Leukemia: Two-Year Follow-up in Eight Clinical Trials
- 1 December 2009
- journal article
- review article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 9 (6), 417-424
- https://doi.org/10.3816/clm.2009.n.083
Abstract
No abstract availableThis publication has 34 references indexed in Scilit:
- Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL MutantsJournal of Clinical Oncology, 2009
- Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat AnalysisJournal of Clinical Oncology, 2008
- A new rapid and sensitive assay for detecting the T315I BCR-ABL kinase domain mutation in chronic myeloid leukaemiaJournal of Clinical Pathology, 2008
- In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinibBlood, 2008
- Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemiaBlood, 2007
- Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABLCancer Chemotherapy and Pharmacology, 2007
- Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)–based mutagenesis screen: high efficacy of drug combinationsBlood, 2006
- The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL MutantsCancer Research, 2006
- In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain MutantsCancer Research, 2005
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004